We are a fully integrated specialty pharmaceutical company engaged in the R&D, manufacturing and commercialization of quality respiratory drug products for the global market.
Breathe Easier. Live Better.
A variety of respiratory system solutions are involved in CF PharmTech's pipeline.
Our therapeutic areas include respiratory diseases such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD), respiratory infections, pulmonary fibrosis, pulmonary hypertension and other respiratory diseases with high clinical need.
It refers to the preparation of the raw material drug or the raw material drug and the additive and the suitable ejector jointly sealed in a pressure container with a quantitative valve system and a c
Solid raw drug alone or mixed with a suitable carrier, in the form of capsules, vesicles or multi-dose storage, using a special dry powder inhalation device, the patient inhales the atomized drug into
The liquid preparation for the nebulizer refers to the solution, suspension or emulsion produced continuously for inhalation aerosol through the nebulizer. The liquid preparation for inhalation includ
It refers to the preparation of the raw material drug or the raw material drug and the additive and the suitable ejector jointly sealed in a pressure container with a quantitative valve system and a c
Solid raw drug alone or mixed with a suitable carrier, in the form of capsules, vesicles or multi-dose storage, using a special dry powder inhalation device, the patient inhales the atomized drug into
The liquid preparation for the nebulizer refers to the solution, suspension or emulsion produced continuously for inhalation aerosol through the nebulizer. The liquid preparation for inhalation includ
On November 17, 2022, the 9th "Best Employers in Greater Suzhou" was officially announced by Suzhou Industrial Park Human Resources Development Co., LTD. With excellent human resource management pract
Today, CF PharmTech, Inc. (hereinafter referred to as: "CF PharmTech") independently developed the heavy product ShuFeiMin® (National drug approval number: H20223778, general
CF PharmTech, Inc. (CF PharmTech, Inc., referred to as "CF PharmTech"), following the completion of the E round of 630 million financing in January, once again completed the F round of 360 million yuan financing, a total of nearly 1 billion financing with